What is the appropriate dose of Augmentin (amoxicillin‑clavulanate) for a male patient with acute otitis media who weighs 118 pounds (≈53 kg)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 12, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Augmentin Dosing for Acute Otitis Media in a 118-lb Male

For an adult male weighing 118 lbs (53.6 kg) with acute otitis media, prescribe Augmentin 875 mg/125 mg twice daily for 10 days, which provides approximately 33 mg/kg/day of amoxicillin—an appropriate adult dosing regimen for respiratory tract infections including otitis media 1, 2.

Rationale for Adult Dosing

  • Standard adult formulation: The 875 mg/125 mg tablet twice daily is the established adult dose for respiratory tract infections, including otitis media 1, 2.

  • Weight-based considerations: At 53.6 kg, this patient falls into the adult dosing category (typically ≥40 kg), where fixed-dose tablets replace pediatric weight-based suspensions 1.

  • Alternative adult regimen: Augmentin XR 2000 mg/125 mg twice daily may be considered for drug-resistant pathogens, though this is typically reserved for more severe infections or treatment failures 2.

Important Clinical Context

First-Line vs. Second-Line Therapy

  • Amoxicillin alone remains first-line: For uncomplicated AOM in adults without recent antibiotic exposure, plain amoxicillin at 500 mg three times daily or 875 mg twice daily is preferred 3.

  • Augmentin is indicated when:

    • The patient received amoxicillin within the past 30 days 4
    • Purulent conjunctivitis co-exists (otitis-conjunctivitis syndrome) 4
    • Coverage for β-lactamase-producing Haemophilus influenzae or Moraxella catarrhalis is needed 4, 2
    • Initial amoxicillin therapy has failed after 48-72 hours 3

Treatment Duration and Monitoring

  • Duration: 10 days of therapy is standard 3, 4.

  • Reassessment timing: Evaluate clinical response at 48-72 hours after initiation 3, 4.

  • Failure criteria: Lack of improvement or worsening after 48-72 hours warrants consideration of alternative therapy, such as intramuscular ceftriaxone 1-2 grams daily 3.

Common Pitfalls to Avoid

  • Pediatric dosing confusion: The high-dose pediatric regimens (80-90 mg/kg/day) cited in guidelines 3, 4 apply to children, not adults. Adult fixed-dose tablets provide adequate coverage without weight-based calculation.

  • Unnecessary high-dose therapy: Augmentin XR (2000/125 mg) is reserved for documented drug-resistant Streptococcus pneumoniae or treatment failures 2, not routine first-episode AOM.

  • Gastrointestinal side effects: Diarrhea occurs in approximately 13% of patients on standard Augmentin formulations 1. Taking the medication with food may reduce GI upset 1.

Alternative Considerations

  • Penicillin allergy: If the patient has a non-type I hypersensitivity reaction to penicillin, cefdinir or cefuroxime are appropriate alternatives 3.

  • True penicillin allergy: For type I hypersensitivity, consider respiratory fluoroquinolones (e.g., levofloxacin 500-750 mg daily) in adults 2.

  • Treatment failure: If no improvement occurs by 48-72 hours, switch to ceftriaxone 1-2 grams IM/IV daily or a respiratory fluoroquinolone 3.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.